Rapid Urine Test Detects Early Kidney Injury
|
By LabMedica International staff writers Posted on 05 May 2014 |
|
Image: The NephroCheck Test cartridge and Astute140 Meter (Photo courtesy of Astute Medical).
A new test utilizes fluorescence immunoassay technology to detect and measure two biomarkers that reflect the risk of developing acute kidney injury (AKI).
The NephroCheck Test measures tissue inhibitor of metalloproteinase 2 (TIMP-2) and insulin-like growth factor binding protein 7(IGFBP-7) in human urine. Both are involved in G1 cell cycle arrest during the very early phases of cellular stress, and are robust measures of risk for AKI manifesting within the following 12-24 hours. TIMP-2 is an inhibitor of the matrix metalloproteinases (MMPs) that directly suppress the proliferation of endothelial cells. IGFBP-7 is involved in the regulation of tissue availability of insulin and IGFs, and stimulates cell adhesion implicated in epithelial cell-cycle arrest.
For the test, a sample of a patient’s urine is mixed with reagents onto a single-use cartridge inserted into the proprietary Astute140 Meter. The meter employs a sandwich immunoassay technique along with fluorescence detection technology to quantitatively measure the biomarker concentrations, combining them into a single numerical test result. Multiple levels of controls (internal, external, and electronic) are used to ensure reliable and accurate results in about 20 minutes. The NephroCheck Test and Astute140 Meter are products of Astute Medical (San Diego, CA, USA), and have received the European Community CE marking of approval.
“We believe the NephroCheck Test will be able to help physicians address one of the most costly, deadly, and confounding conditions affecting intensive care hospital patients,” said Chris Hibberd, CEO of Astute Medical. “With increasing constraints on healthcare spending, innovative tools such as the NephroCheck Test will be essential to ensuring that the right resources get to the right patients at the right time.”
AKI is a significant global health hazard that strikes up to seven percent of hospitalized patients. AKI often occurs in patients that are already suffering from myriad issues such as sepsis, trauma, surgery, or being treated with nephrotoxic drugs, further complicating diagnosis, while also increasing mortality rates.
Related Links:
Astute Medical
 assay.jpg)
The NephroCheck Test measures tissue inhibitor of metalloproteinase 2 (TIMP-2) and insulin-like growth factor binding protein 7(IGFBP-7) in human urine. Both are involved in G1 cell cycle arrest during the very early phases of cellular stress, and are robust measures of risk for AKI manifesting within the following 12-24 hours. TIMP-2 is an inhibitor of the matrix metalloproteinases (MMPs) that directly suppress the proliferation of endothelial cells. IGFBP-7 is involved in the regulation of tissue availability of insulin and IGFs, and stimulates cell adhesion implicated in epithelial cell-cycle arrest.
For the test, a sample of a patient’s urine is mixed with reagents onto a single-use cartridge inserted into the proprietary Astute140 Meter. The meter employs a sandwich immunoassay technique along with fluorescence detection technology to quantitatively measure the biomarker concentrations, combining them into a single numerical test result. Multiple levels of controls (internal, external, and electronic) are used to ensure reliable and accurate results in about 20 minutes. The NephroCheck Test and Astute140 Meter are products of Astute Medical (San Diego, CA, USA), and have received the European Community CE marking of approval.
“We believe the NephroCheck Test will be able to help physicians address one of the most costly, deadly, and confounding conditions affecting intensive care hospital patients,” said Chris Hibberd, CEO of Astute Medical. “With increasing constraints on healthcare spending, innovative tools such as the NephroCheck Test will be essential to ensuring that the right resources get to the right patients at the right time.”
AKI is a significant global health hazard that strikes up to seven percent of hospitalized patients. AKI often occurs in patients that are already suffering from myriad issues such as sepsis, trauma, surgery, or being treated with nephrotoxic drugs, further complicating diagnosis, while also increasing mortality rates.
Related Links:
Astute Medical
Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
New
Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay
Laboratory Software
ArtelWare
Latest Clinical Chem. News
- Chemical Imaging Probe Could Track and Treat Prostate Cancer
- Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
- VOCs Show Promise for Early Multi-Cancer Detection
- Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
- Gold Nanoparticles to Improve Accuracy of Ovarian Cancer Diagnosis
- Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy
- Simple Non-Invasive Hair-Based Test Could Speed ALS Diagnosis
- Paper Strip Saliva Test Detects Elevated Uric Acid Levels Without Blood Draws
- Prostate Cancer Markers Based on Chemical Make-Up of Calcifications to Speed Up Detection
- Breath Test Could Help Detect Blood Cancers
- ML-Powered Gas Sensors to Detect Pathogens and AMR at POC
- Saliva-Based Cancer Detection Technology Eliminates Need for Complex Sample Preparation
- Skin Swabs Could Detect Parkinson’s Years Before Symptoms Appear
- New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs
- New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
- Pen-Like Tool Quickly and Non-Invasively Detects Opioids from Skin
Channels
Molecular Diagnostics
view channel
Genetic Marker to Help Children with T-Cell Leukemia Avoid Unnecessary Chemotherapy
About 400 children in the UK are diagnosed with acute lymphoblastic leukemia (ALL) each year, with roughly 15% presenting with a more aggressive T-ALL subtype. While the standard approach is a four-week... Read more
Four-Gene Blood Test Rules Out Bacterial Lung Infection
Lower respiratory tract infections (LRTIs) are among the most common reasons for antibiotic prescriptions, yet distinguishing bacterial infections from viral ones remains notoriously difficult.... Read more
New PCR Test Improves Diagnostic Accuracy of Bacterial Vaginosis and Candida Vaginitis
Bacterial vaginosis (BV) impacts approximately 25% of women of reproductive age, while up to 75% of women experience candida vaginitis (CV) at least once in their lifetime. Vaginal symptoms are one of... Read more
Hematology
view channel
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more
Immunology
view channel
New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
Since HIV was identified in 1983, more than 91 million people have contracted the virus, and over 44 million have died from related causes. Today, nearly 40 million individuals worldwide live with HIV-1,... Read more
Gene Signature Test Predicts Response to Key Breast Cancer Treatment
DK4/6 inhibitors paired with hormone therapy have become a cornerstone treatment for advanced HR+/HER2– breast cancer, slowing tumor growth by blocking key proteins that drive cell division.... Read more
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read more
Microbiology
view channel
Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
Sepsis kills 11 million people worldwide every year and generates massive healthcare costs. In the USA and Europe alone, sepsis accounts for USD 100 billion in annual hospitalization expenses.... Read more
Rapid POC Tuberculosis Test Provides Results Within 15 Minutes
Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more
Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read more
Pathology
view channel
AI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities
Diagnosing blood disorders depends on recognizing subtle abnormalities in cell size, shape, and structure, yet this process is slow, subjective, and requires years of expert training. Even specialists... Read more
AI Tool Rapidly Analyzes Complex Cancer Images for Personalized Treatment
Complex digital biopsy images that typically take an expert pathologist up to 20 minutes to assess can now be analyzed in about one minute using a new artificial intelligence (AI) tool. The technology... Read more
Technology
view channel
Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Identifying which genetic variants actually cause disease remains one of the biggest challenges in genomic medicine. Each person carries tens of thousands of DNA changes, yet only a few meaningfully alter... Read more
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read more
Industry
view channel
Abbott Acquires Cancer-Screening Company Exact Sciences
Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more
